These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 21733737

  • 1. Tardive syndrome and Parkinson's disease responsive to concomitant tetrabenazine and levodopa therapy.
    Kurtis MM, Franch O.
    Parkinsonism Relat Disord; 2011 Dec; 17(10):774-6. PubMed ID: 21733737
    [No Abstract] [Full Text] [Related]

  • 2. [Motor fluctuations in Parkinson's disease: the "New frontier" of therapeutic success. A Roche Laboratory seminar].
    d'Anglejan Chatillon J.
    Rev Prat; 1989 Mar 09; 39(8):689-90. PubMed ID: 2727575
    [No Abstract] [Full Text] [Related]

  • 3. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
    Ruggieri S, Fabbrini G, Bramante L, DePandis F, Stocchi F, Barbanti P, Vacca L, Manfredi M.
    Adv Neurol; 1996 Mar 09; 69():595-8. PubMed ID: 8615185
    [No Abstract] [Full Text] [Related]

  • 4. [Treatment of Parkinson's disease and extrapyramidal syndromes with classical drugs (what can be expected from them in the levodopa era and which should be used)].
    Sigwald J.
    Therapeutique; 1972 Nov 09; 48(9):561-8. PubMed ID: 4650525
    [No Abstract] [Full Text] [Related]

  • 5. How best to address these common movement disorders.
    Yaman A, Akdeniz M, Yaman H.
    J Fam Pract; 2011 Dec 09; 60(12):721-5. PubMed ID: 22163354
    [No Abstract] [Full Text] [Related]

  • 6. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A, Trenkwalder C, Oehlwein C, Winkelmann J, Polzer U, Hundemer HP, Schwarz J.
    Parkinsonism Relat Disord; 2005 Sep 09; 11(6):393-8. PubMed ID: 15993640
    [Abstract] [Full Text] [Related]

  • 7. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort InvestigatorsDepartment of Neurology, University of Rochester, 1351 Mt Hope Ave, Ste 220, Rochester, NY 14620, USA. kevin.biglan@ctcc.rochester.edu.
    Arch Neurol; 2009 May 09; 66(5):563-70. PubMed ID: 19433655
    [Abstract] [Full Text] [Related]

  • 8. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.
    Walker RW, Howells AR, Gray WK.
    Parkinsonism Relat Disord; 2011 Jan 09; 17(1):27-9. PubMed ID: 21051272
    [Abstract] [Full Text] [Related]

  • 9. Medical management of motor fluctuations.
    Dewey RB.
    Neurol Clin; 2008 Aug 09; 26(3 Suppl):S15-27, v. PubMed ID: 18774440
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological strategies for controlling motor fluctuations in Parkinson's disease.
    Ruggieri S, Carta A, Stocchi F, Antonini A, Bellantuono P, Monge A.
    Funct Neurol; 1988 Aug 09; 3(4):471-9. PubMed ID: 3072281
    [No Abstract] [Full Text] [Related]

  • 11. Parkinson's disease.
    Barboi AC, Goetz CG.
    Clin Neuropharmacol; 1999 Aug 09; 22(4):184-91. PubMed ID: 10442246
    [No Abstract] [Full Text] [Related]

  • 12. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
    Sage JI, Mark MH.
    Ann Neurol; 1991 Oct 09; 30(4):616-7. PubMed ID: 1789688
    [Abstract] [Full Text] [Related]

  • 13. Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients.
    Sánchez-Castañeda C, Campdelacreu J, Miró J, Juncadella M, Jaumà S, Calopa M.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb 01; 34(1):250-1. PubMed ID: 19887096
    [No Abstract] [Full Text] [Related]

  • 14. Dysphagia in Parkinson's disease is responsive to levodopa.
    Sutton JP.
    Parkinsonism Relat Disord; 2013 Mar 01; 19(3):282-4. PubMed ID: 23333537
    [Abstract] [Full Text] [Related]

  • 15. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.
    Meco G, Bernardi S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan 30; 31(1):311-3. PubMed ID: 16919377
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of early Parkinson's disease. Part 1.
    Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D.
    Eur Neurol; 2009 Jan 30; 61(4):193-205. PubMed ID: 19176960
    [Abstract] [Full Text] [Related]

  • 18. The effects of levodopa on word intelligibility in Parkinson's disease.
    De Letter M, Santens P, Van Borsel J.
    J Commun Disord; 2005 Jan 30; 38(3):187-96. PubMed ID: 15748723
    [Abstract] [Full Text] [Related]

  • 19. Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease.
    Baron MS, Dalton WB.
    Mov Disord; 2003 Oct 30; 18(10):1208-9. PubMed ID: 14534933
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R, Koller WC.
    Adv Neurol; 1996 Oct 30; 69():487-91. PubMed ID: 8615169
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.